Updates on the FLT3 inhibitor FF-10101 for the treatment of R/R AML

FF-10101-01: a novel FLT3 inhibitor for R/R AMLПодробнее

Novel FLT3 inhibitors for AMLПодробнее

Treatment avenues for patients with R/R FLT3-mutated AML: optimizing FLT3 inhibitorsПодробнее

Novel treatment combinations for FLT3-mutated AMLПодробнее

Targeted therapies in newly diagnosed AML: BCL2, FLT3 and IDH inhibitorsПодробнее

FLT3 inhibitors as maintenance therapy in AMLПодробнее

The use of FLT3 inhibitors in AMLПодробнее

Continuous treatment with FLT3 inhibitors for patients with FLT3-mutated AML undergoing alloSCTПодробнее

Dr. Erba on FLT3 Inhibitors for the Treatment of AMLПодробнее

Optimizing the use of FLT3 inhibitors in AML: sequencing, post-transplant maintenance & moreПодробнее

Optimizing Use of FLT3 Inhibitor Therapy for AMLПодробнее

FLT3 Inhibitors Impact Treatment Landscape for Patients With FLT3-Mutated AMLПодробнее

Combinations with FLT3 inhibitors: the way forward for AML treatmentПодробнее

Comparing midostaurin to next-generation FLT3 inhibitors in the frontline treatment of FLT3-ITD AMLПодробнее

FLT3 inhibitor maintenance after allo-SCT for AMLПодробнее

FLT3 Inhibitors in the Therapy of Acute Myeloid LeukemiaПодробнее

COMMODORE: gilteritinib for the treatment of R/R FLT3-mutated AMLПодробнее

Resistance mechanisms to FLT3 inhibitors in AMLПодробнее

FLT3 inhibitors in the treatment of AMLПодробнее